Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1692 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed912    
    Printed42    
    Emailed0    
    PDF Downloaded138    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 1999  |  Volume : 41  |  Issue : 1  |  Page : 49-53

Catatonic Syndrome : Treatment Response to Lorazepam


1 Senior Resident, Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605006, India
2 Head of the Department, Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605006, India
3 B.S., Non Postgraduate Junior Resident in Psychiatry, Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605006, India

Correspondence Address:
R Chandrasekaran
Head of the Department, Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605006
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21455353

Rights and PermissionsRights and Permissions

In a prospective open trial, 30 inpatients with catatonic signs were treated systematically with oral lorazepam (dosage ranging between 3 to 8 mg/d) for a period of 5 days and subsequently with ECT if lorazepam trial failed. Outcome was monitored quantitatively during the treatment phase with Bush-Francis catatonia rating scale. In 21 out of 30 patients (70%), catatonic signs resolved with lorazepam trial. The response to lorazepam on Day 1, predicted the final outcome. Demographic variables, severity of catatonia or length of catatonic syndrome prior to treatment did not have any predictive value. Majority of the patients who showed an unfavourable response, did well with electroconvulsive therapy. A short duration lorazepam administration proved to be a safe and effective treatment for the catatonic syndrome.



[PDF]*

        

Print this article         Email this article